Immune Cell Engager Partnering and Investment Summit on September 30-October 01, 2025 in Boston, United States

The Immune Cell Engager Partnering and Investment Summit is here. As part of the game-changing Partnering and Investment Series, it's the first-ever partnering forum for next-gen engager deal-making. It brings together top biotech companies leading engager and multispecific innovation, pharma leaders, and investors for hyper-aligned and more efficient business networking.

Unite with other immune cell engager business development leaders where cutting-edge science meets strategic networking to:

Capitalize on protected face-to-face networking with a 100% aligned audience and the One-on-One Partnering platform, to efficiently generate higher-yielding deal opportunities and nurture multiple key relationships in a less competitive forum

Understand assessment criteria, data package expectations, and due diligence of pharma and investors, and hear invaluable feedback into your financing or development programs

Evaluate the total landscape of emerging engager assets to refine your points of differentiation, discuss collaboration and licensing options with similar stakeholders seeking creative partnerships to validate technologies or de-risk asset development

URLs:

Tickets: https://go.evvnt.com/3125875-2?pid=10008

Brochure: https://go.evvnt.com/3125875-3?pid=10008

Time: 8:00 AM - 4:00 PM

Prices:

Drug Developer Pricing - Two Day Attendance and Access to Partnering Portal: USD 2999.00,

Academic Pricing - Two Day Attendance and Access to Partnering Portal: USD 2599.00,

Solution Provider Pricing - : USD 5299.00

Speakers: Divya Chaudhary, Director, Search and Evaluation, Immunology AbbVie, Nik Misljencevic, Director, Business Development AbCellera, Jak Knowles, Co-Founder, President and Chief Executive Officer, Affini-T Therapeutics, Nikhil Mutyal, Executive Director and Head of Search and Evaluation, R and I AstraZeneca , David Fang, Senior Director, Search and Evaluation AstraZeneca, Swarna Balasubramanian, Associate Director - Search, Evaluation, Business Development, Respiratory and Immunology AstraZeneca, Tim Lu, Chief Medical Officer and Chief Scientific Officer Candid Therapeutics, Arvind Kush, Chief Financial Officer and Chief Business Officer, Candid Therapeutics, Sarah Holland, Chief Business Officer, CDR Life, Julie DeSander, Chief Business Officer, Clasp Therapeutics, Geraldine Paulus, Co-Founder, Vice President, Head of Corporate Development and Operations, Crossbow Therapeutics, Harold E. "Barry" Selick, Chief Executive Officer, Hinge Bio, William Ho, Co-Founder and Chief Executive Officer, IN8bio, Andy Meyer, Chief Business Officer, Janux Therapeutics, James Field, Chief Executive Officer, LabGenius Therapeutics, Annie Vemu, Senior Associate, Longwood Fund, Shiva Bolourchi, Executive Director, Head of Corporate Strategy and Partnerships, Marengo Therapeutics, Christopher Tan, Executive Director, Search and Evaluation, Business Development, Licensing, Infectious Diseases, Vaccines and Oncology, Merck, Giovanni Abbadessa, Chief Medical Officer, Modex Therapeutics, Venky Raghavan, Executive Director, Search and Evaluation, Oncology Novartis, Xiaodong Zhang, Business Development Search and Evaluation, Oncology and Hematology, Novartis, Christina Carlson, General Counsel and Chief Administrative Officer, Ouro Medicines, John Delyani, Chief Business Officer, Repertoire Immune Medicines, Meghana Rao, VP of Business Development, Rondo Therapeutics, Saifur Rahman, Director, Search and Evaluation Immunology, Sanofi, Shinji Okitsu, External Immunology Lead, I and I Research, Sanofi , Avnish Kapoor, VP, Head of Portfolio Strategy and Business Development , SystImmune, Thomas Lars Andresen, Chief Executive Officer, T-Cypher Bio, Ross Castillo, Principal, Biotech Private Investments, Wellington Management Company, Jayanth Batchu, Associate and Entrepreneur in Residence, Xontogeny, David Kroeger, Associate Director, Business Development, Zymeworks